PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30707764-0	2019	Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2.	Lenalidomide	17-29	BCL2 apoptosis regulator	Homo sapiens	127-131	
23012246-7	2012	RSK2(Ser227) inhibition resulting from BI-D1870 treatment restored lenalidomide-induced direct cytotoxicity of myeloma cells from interleukin-6-mediated cell protection, showed no cross-resistance to bortezomib, and exerted additive/synergistic antiproliferative effects in conjunction with the mTOR, histone deacetylase, and BH3-mimicking BCL2/BCLX(L) inhibitors.	Lenalidomide	67-79	BCL2 apoptosis regulator	Homo sapiens	340-344	
24236538-7	2014	This cytotoxic effect and BCL2 downregulation were further potentiated when AT-101 was combined with lenalidomide/dexamethasone (LDA).	Lenalidomide	101-113	BCL2 apoptosis regulator	Homo sapiens	26-30	
22109882-0	2012	The immunomodulatory drug lenalidomide restores a vitamin D sensitive phenotype to the vitamin D resistant breast cancer cell line MDA-MB-231 through inhibition of BCL-2: potential for breast cancer therapeutics.	Lenalidomide	26-38	BCL2 apoptosis regulator	Homo sapiens	164-169	
22171982-0	2012	Downregulation of BCL2 by AT-101 enhances the antileukaemic effect of lenalidomide both by an immune dependant and independent manner.	Lenalidomide	70-82	BCL2 apoptosis regulator	Homo sapiens	18-22	
22109882-10	2012	An apoptosis protein array showed that the 1,25-D3 and lenalidomide combination increased pro-apoptotic proteins (phosphorylated p53) and decreased BCL-2 expression.	Lenalidomide	55-67	BCL2 apoptosis regulator	Homo sapiens	148-153